[Treatment of Cystic Fibrosis with CFTR Modulators]

Area of Science:

• Biochemistry
• Genetics
• Pharmacology

Background:

• Cystic fibrosis (CF) is an inherited disorder affecting chloride and bicarbonate transport.
• It results from mutations in the CFTR gene, impacting exocrine glands.
• Personalized medicine tailors treatments to individual patients, exemplified by CFTR modulators.

Purpose of the Study:

• To provide an overview of cystic fibrosis and CFTR modulator development.
• To discuss the basic defect, population genetics, and bioassays for CFTR function.
• To highlight achievements in preclinical and clinical research for CFTR modulators.

Main Methods:

• Review of CFTR modulator classes: potentiators and correctors.
• Analysis of approved drugs (ivacaftor, lumacaftor) for specific CFTR mutations.
• Summary of preclinical research and clinical trial outcomes.
• Discussion of bioassays for assessing CFTR function in humans.

Main Results:

• Ivacaftor and lumacaftor are approved for specific CF mutations in Germany.
• CFTR modulators demonstrate successful mutation-specific therapy for cystic fibrosis.
• Significant progress has been made in bringing CFTR modulators from bench to bedside.

Conclusions:

• CFTR modulators represent a successful example of personalized medicine in cystic fibrosis.
• Continued research addresses challenges and explores novel strategies for modulator development.
• Understanding CFTR mutation genetics is crucial for targeted therapeutic approaches.